RNA Avidity Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RNA

Price (delayed)

$23.04

Market cap

$1.84B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.91

Enterprise value

$1.66B

Avidity Biosciences, Inc. is driven to change lives with a new class of therapies called Antibody Oligonucleotide Conjugates (AOCs) that are designed to overcome current limitations of oligonucleotide therapies in ...

Highlights
RNA's EPS is up by 13% YoY and by 3% from the previous quarter
Avidity Biosciences's debt has decreased by 8% YoY and by 7% from the previous quarter
RNA's revenue is down by 6% since the previous quarter but it is up by 3.6% year-on-year
The gross profit fell by 6% QoQ but it rose by 3.6% YoY
RNA's quick ratio is down by 37% YoY and by 34% from the previous quarter
RNA's net income is down by 22% YoY and by 4.9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.aviditybiosciences.com
Peers: PTCT SRPT FATE PFE

Key stats

What are the main financial stats of RNA
Market
Shares outstanding
79.72M
Market cap
$1.84B
Enterprise value
$1.66B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.41
Price to sales (P/S)
175.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
173.77
Earnings
Revenue
$9.56M
EBIT
-$212.22M
EBITDA
-$207.14M
Free cash flow
-$123.29M
Per share
EPS
-$2.91
Free cash flow per share
-$1.69
Book value per share
$6.76
Revenue per share
$0.13
TBVPS
$8.61
Balance sheet
Total assets
$628.56M
Total liabilities
$127.79M
Debt
$9.85M
Equity
$500.76M
Working capital
$530.63M
Liquidity
Debt to equity
0.02
Current ratio
7.58
Quick ratio
7.38
Net debt/EBITDA
0.85
Margins
EBITDA margin
-2,166.7%
Gross margin
100%
Net margin
-2,219.9%
Operating margin
-2,464.4%
Efficiency
Return on assets
-35%
Return on equity
-39.7%
Return on invested capital
-50%
Return on capital employed
-38.7%
Return on sales
-2,219.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RNA stock price

How has the Avidity Biosciences stock price performed over time
Intraday
-2.17%
1 week
-9.11%
1 month
-3.72%
1 year
42.93%
YTD
154.59%
QTD
-9.72%

Financial performance

How have Avidity Biosciences's revenue and profit performed over time
Revenue
$9.56M
Gross profit
$9.56M
Operating income
-$235.6M
Net income
-$212.22M
Gross margin
100%
Net margin
-2,219.9%
The operating income has contracted by 32% YoY and by 6% from the previous quarter
RNA's operating margin is down by 27% year-on-year and by 12% since the previous quarter
RNA's net income is down by 22% YoY and by 4.9% QoQ
Avidity Biosciences's net margin has decreased by 18% YoY and by 11% from the previous quarter

Growth

What is Avidity Biosciences's growth rate over time

Valuation

What is Avidity Biosciences stock price valuation
P/E
N/A
P/B
3.41
P/S
175.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
173.77
RNA's EPS is up by 13% YoY and by 3% from the previous quarter
The P/B is 144% above the last 4 quarters average of 1.4
The equity fell by 13% YoY and by 3.2% QoQ
RNA's P/S is 128% above its last 4 quarters average of 77.1
RNA's revenue is down by 6% since the previous quarter but it is up by 3.6% year-on-year

Efficiency

How efficient is Avidity Biosciences business performance
RNA's return on invested capital is up by 25% year-on-year and by 2.2% since the previous quarter
RNA's ROS is down by 18% YoY and by 11% from the previous quarter
The ROE has contracted by 9% from the previous quarter but it has grown by 2.7% YoY
RNA's ROA is down by 5% from the previous quarter but it is up by 3.8% YoY

Dividends

What is RNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RNA.

Financial health

How did Avidity Biosciences financials performed over time
RNA's total liabilities has surged by 129% since the previous quarter and by 110% year-on-year
RNA's quick ratio is down by 37% YoY and by 34% from the previous quarter
Avidity Biosciences's debt is 98% less than its equity
The equity fell by 13% YoY and by 3.2% QoQ
Avidity Biosciences's debt has decreased by 8% YoY and by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.